{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "ff67d68a",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "139b92b2",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The latest guidelines for hypertension control in patients with Type 2 Diabetes Mellitus (T2DM) emphasize individualized blood pressure targets and comprehensive management strategies including lifestyle modifications and pharmacological interventions.\n",
      "\n",
      "Key recommendations from major organizations include:\n",
      "\n",
      "**Blood Pressure Targets:**\n",
      "*   **European Society of Cardiology (ESC) 2024 Guidelines:** Recommend a target office systolic blood pressure (SBP) of 120–129 mmHg and diastolic blood pressure (DBP) of 70–79 mmHg for most patients with diabetes, if feasible and tolerated. For older patients (age ≥65 years), the target SBP should be 130–139 mmHg if tolerated. The DBP target for all treated patients is <80 mmHg. Pharmacological treatment is recommended for those with confirmed hypertension (office BP ≥140/90 mmHg) and for those with office BP ≥130/80 mmHg after a maximum of three months of lifestyle intervention to reduce cardiovascular disease (CVD) risk. An on-treatment SBP target of <130 mmHg may be considered for patients at particularly high risk of a cerebrovascular event to further reduce stroke risk.\n",
      "*   **American Diabetes Association (ADA) 2022 Guidelines:** Advise that blood pressure should be controlled to <140/90 mmHg for most patients with diabetes. However, a more intensive target of <130/80 mmHg is recommended if there is a higher cardiovascular (CV) risk, existing atherosclerotic cardiovascular disease (ASCVD), or a 10-year ASCVD risk of ≥15%. The ADA's Standards of Care in Diabetes—2023 redefined hypertension as a blood pressure ≥130/80 mmHg and advised a target blood pressure for people with diabetes to be below 130/80 mmHg if it can be safely achieved.\n",
      "*   **American College of Cardiology/American Heart Association (ACC/AHA) 2017 Guidelines:** Recommend a target blood pressure of <130/80 mmHg for patients with hypertension, which also applies to those with diabetes mellitus. For adults with stage I hypertension (BP 130-139/80-89 mmHg) and an estimated 10-year ASCVD risk of <10%, nonpharmacologic therapy is recommended. For those with a 10% or higher 10-year ASCVD risk, the use of BP-lowering medication with a BP target of <130/80 mmHg is recommended, including persons with chronic kidney disease and diabetes.\n",
      "\n",
      "**Lifestyle Interventions:**\n",
      "All major guidelines emphasize the importance of lifestyle modifications as a cornerstone of hypertension management in T2DM patients. These include:\n",
      "*   Weight loss for overweight or obese individuals.\n",
      "*   Adopting a Dietary Approaches to Stop Hypertension (DASH)-style eating pattern, which involves reduced sodium and increased potassium intake, and increased fruit and vegetable consumption.\n",
      "*   Moderation of alcohol intake.\n",
      "*   Increased physical activity (at least 150 minutes/week of moderate to vigorous physical activity, including aerobic and resistance exercise).\n",
      "\n",
      "**Pharmacological Treatment:**\n",
      "*   For patients with confirmed hypertension (office BP ≥140/90 mmHg) or SBP 130–139 mmHg after 3 months of lifestyle interventions, antihypertensive drug therapy should be initiated.\n",
      "*   The first-line treatment typically involves a combination of two drugs, often a renin-angiotensin system (RAS) inhibitor (ACE inhibitors or ARBs) and either a calcium channel blocker (CCB) or a thiazide/thiazide-like diuretic. ACE inhibitors or ARBs are particularly warranted due to their potential benefits in slowing albuminuria and progression to kidney failure, which is common in diabetes.\n",
      "*   Single-pill combinations are recommended to improve adherence and efficacy.\n",
      "*   New antidiabetic drugs, such as Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors and Glucagon-Like Peptide 1 (GLP-1) agonists, have been found to lower blood pressure in addition to their glucose-lowering effects and improve cardiovascular and renal outcomes. The ESC 2024 guidelines specifically recognize the growing evidence supporting the use of SGLT2 inhibitors in hypertensive patients with coexisting conditions like chronic kidney disease, T2DM, and heart failure for dual benefits of BP control and CV risk reduction.\n",
      "*   For resistant hypertension, mineralocorticoid receptor antagonists (MRAs) like spironolactone may be added.\n",
      "\n",
      "**Monitoring:**\n",
      "*   Blood pressure should be measured at every routine clinical care visit.\n",
      "*   Home blood pressure monitoring is recommended to identify white-coat hypertension and monitor control.\n",
      "*   Orthostatic blood pressure measurement should be performed during initial evaluation and periodically, or if symptoms of orthostatic hypotension are present.\n",
      "<style>\n",
      ".container {\n",
      "  align-items: center;\n",
      "  border-radius: 8px;\n",
      "  display: flex;\n",
      "  font-family: Google Sans, Roboto, sans-serif;\n",
      "  font-size: 14px;\n",
      "  line-height: 20px;\n",
      "  padding: 8px 12px;\n",
      "}\n",
      ".chip {\n",
      "  display: inline-block;\n",
      "  border: solid 1px;\n",
      "  border-radius: 16px;\n",
      "  min-width: 14px;\n",
      "  padding: 5px 16px;\n",
      "  text-align: center;\n",
      "  user-select: none;\n",
      "  margin: 0 8px;\n",
      "  -webkit-tap-highlight-color: transparent;\n",
      "}\n",
      ".carousel {\n",
      "  overflow: auto;\n",
      "  scrollbar-width: none;\n",
      "  white-space: nowrap;\n",
      "  margin-right: -12px;\n",
      "}\n",
      ".headline {\n",
      "  display: flex;\n",
      "  margin-right: 4px;\n",
      "}\n",
      ".gradient-container {\n",
      "  position: relative;\n",
      "}\n",
      ".gradient {\n",
      "  position: absolute;\n",
      "  transform: translate(3px, -9px);\n",
      "  height: 36px;\n",
      "  width: 9px;\n",
      "}\n",
      "@media (prefers-color-scheme: light) {\n",
      "  .container {\n",
      "    background-color: #fafafa;\n",
      "    box-shadow: 0 0 0 1px #0000000f;\n",
      "  }\n",
      "  .headline-label {\n",
      "    color: #1f1f1f;\n",
      "  }\n",
      "  .chip {\n",
      "    background-color: #ffffff;\n",
      "    border-color: #d2d2d2;\n",
      "    color: #5e5e5e;\n",
      "    text-decoration: none;\n",
      "  }\n",
      "  .chip:hover {\n",
      "    background-color: #f2f2f2;\n",
      "  }\n",
      "  .chip:focus {\n",
      "    background-color: #f2f2f2;\n",
      "  }\n",
      "  .chip:active {\n",
      "    background-color: #d8d8d8;\n",
      "    border-color: #b6b6b6;\n",
      "  }\n",
      "  .logo-dark {\n",
      "    display: none;\n",
      "  }\n",
      "  .gradient {\n",
      "    background: linear-gradient(90deg, #fafafa 15%, #fafafa00 100%);\n",
      "  }\n",
      "}\n",
      "@media (prefers-color-scheme: dark) {\n",
      "  .container {\n",
      "    background-color: #1f1f1f;\n",
      "    box-shadow: 0 0 0 1px #ffffff26;\n",
      "  }\n",
      "  .headline-label {\n",
      "    color: #fff;\n",
      "  }\n",
      "  .chip {\n",
      "    background-color: #2c2c2c;\n",
      "    border-color: #3c4043;\n",
      "    color: #fff;\n",
      "    text-decoration: none;\n",
      "  }\n",
      "  .chip:hover {\n",
      "    background-color: #353536;\n",
      "  }\n",
      "  .chip:focus {\n",
      "    background-color: #353536;\n",
      "  }\n",
      "  .chip:active {\n",
      "    background-color: #464849;\n",
      "    border-color: #53575b;\n",
      "  }\n",
      "  .logo-light {\n",
      "    display: none;\n",
      "  }\n",
      "  .gradient {\n",
      "    background: linear-gradient(90deg, #1f1f1f 15%, #1f1f1f00 100%);\n",
      "  }\n",
      "}\n",
      "</style>\n",
      "<div class=\"container\">\n",
      "  <div class=\"headline\">\n",
      "    <svg class=\"logo-light\" width=\"18\" height=\"18\" viewBox=\"9 9 35 35\" fill=\"none\" xmlns=\"http://www.w3.org/2000/svg\">\n",
      "      <path fill-rule=\"evenodd\" clip-rule=\"evenodd\" d=\"M42.8622 27.0064C42.8622 25.7839 42.7525 24.6084 42.5487 23.4799H26.3109V30.1568H35.5897C35.1821 32.3041 33.9596 34.1222 32.1258 35.3448V39.6864H37.7213C40.9814 36.677 42.8622 32.2571 42.8622 27.0064V27.0064Z\" fill=\"#4285F4\"/>\n",
      "      <path fill-rule=\"evenodd\" clip-rule=\"evenodd\" d=\"M26.3109 43.8555C30.9659 43.8555 34.8687 42.3195 37.7213 39.6863L32.1258 35.3447C30.5898 36.3792 28.6306 37.0061 26.3109 37.0061C21.8282 37.0061 18.0195 33.9811 16.6559 29.906H10.9194V34.3573C13.7563 39.9841 19.5712 43.8555 26.3109 43.8555V43.8555Z\" fill=\"#34A853\"/>\n",
      "      <path fill-rule=\"evenodd\" clip-rule=\"evenodd\" d=\"M16.6559 29.8904C16.3111 28.8559 16.1074 27.7588 16.1074 26.6146C16.1074 25.4704 16.3111 24.3733 16.6559 23.3388V18.8875H10.9194C9.74388 21.2072 9.06992 23.8247 9.06992 26.6146C9.06992 29.4045 9.74388 32.022 10.9194 34.3417L15.3864 30.8621L16.6559 29.8904V29.8904Z\" fill=\"#FBBC05\"/>\n",
      "      <path fill-rule=\"evenodd\" clip-rule=\"evenodd\" d=\"M26.3109 16.2386C28.85 16.2386 31.107 17.1164 32.9095 18.8091L37.8466 13.8719C34.853 11.082 30.9659 9.3736 26.3109 9.3736C19.5712 9.3736 13.7563 13.245 10.9194 18.8875L16.6559 23.3388C18.0195 19.2636 21.8282 16.2386 26.3109 16.2386V16.2386Z\" fill=\"#EA4335\"/>\n",
      "    </svg>\n",
      "    <svg class=\"logo-dark\" width=\"18\" height=\"18\" viewBox=\"0 0 48 48\" xmlns=\"http://www.w3.org/2000/svg\">\n",
      "      <circle cx=\"24\" cy=\"23\" fill=\"#FFF\" r=\"22\"/>\n",
      "      <path d=\"M33.76 34.26c2.75-2.56 4.49-6.37 4.49-11.26 0-.89-.08-1.84-.29-3H24.01v5.99h8.03c-.4 2.02-1.5 3.56-3.07 4.56v.75l3.91 2.97h.88z\" fill=\"#4285F4\"/>\n",
      "      <path d=\"M15.58 25.77A8.845 8.845 0 0 0 24 31.86c1.92 0 3.62-.46 4.97-1.31l4.79 3.71C31.14 36.7 27.65 38 24 38c-5.93 0-11.01-3.4-13.45-8.36l.17-1.01 4.06-2.85h.8z\" fill=\"#34A853\"/>\n",
      "      <path d=\"M15.59 20.21a8.864 8.864 0 0 0 0 5.58l-5.03 3.86c-.98-2-1.53-4.25-1.53-6.64 0-2.39.55-4.64 1.53-6.64l1-.22 3.81 2.98.22 1.08z\" fill=\"#FBBC05\"/>\n",
      "      <path d=\"M24 14.14c2.11 0 4.02.75 5.52 1.98l4.36-4.36C31.22 9.43 27.81 8 24 8c-5.93 0-11.01 3.4-13.45 8.36l5.03 3.85A8.86 8.86 0 0 1 24 14.14z\" fill=\"#EA4335\"/>\n",
      "    </svg>\n",
      "    <div class=\"gradient-container\"><div class=\"gradient\"></div></div>\n",
      "  </div>\n",
      "  <div class=\"carousel\">\n",
      "    <a class=\"chip\" href=\"https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXFxft0cJRUm_kJICWRbpDZesGiPeci0hVcA09s2Nxq0Kfotvxj-85DFOVvHAzFT1NjQOwKeFzq8ftoI41iOMTK43Br2vvXyAGv3XKlK36Dw_qZzgZ9yyLDKbTrYu-n9GS0PiyF5uA0dBClSR0cEfESh0g30ic1qye3tt7uaebWpjxAVOhCUXViO8VcjI2s6zdXkf2vg7DR4oyuM2Cr3Ew==\">ESC guidelines hypertension T2DM</a>\n",
      "    <a class=\"chip\" href=\"https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXHhimBqvJgK5KZYr6szPe4HJsmMBrc18qKmSxbcT1rDHuD4iBkBQGQSRS2D5GLmdbj7XX3eKN-MKtl9nGAD4o0_e7DRFsvl0PKbIaB6UkQdNFS8p6DScfa72b1Oj6_8LKVK0VMH3lRQFmF-YFzXv9y7kWmEls6OWOedGxUD2QY7SjLlPSiCLSP4UNl-BoQ6kpHo8IKUFAap3WQrM4tOFg==\">AHA guidelines hypertension T2DM</a>\n",
      "    <a class=\"chip\" href=\"https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEAD3faWo8qKB04QYPCLW4umr1-CdVndbPfafZGou3TPknUc2vAaYEPZXD8cGE9bg6mBB1jAamIFCyufADwcbmMWCn514ZG3UVKcC8SVJX-rWUr0Ti0CmCArcppIfi5j9mRlFxje806ielwd7k32gBnDdHSuF4GjtGPWh_WhWorRFpqz0gtKP3JOzr7Z1193AwZKjRARvbh7aFThrJHBRAAw_EHBq3Th3TL-qWeXV_6gxIQn5Dr\">latest guidelines hypertension control type 2 diabetes</a>\n",
      "    <a class=\"chip\" href=\"https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEdHOZ1irKo4Jng_WSm8Ugi25eDl0kiwajVjEYBf4FRVc4bzPzCElzKc6YJp-cvLfMGNg8mVB6zD0MjcqbKL658ZFIM9b-xPjVD4qQobUyt6AxSQEJdU5DDUmJWDMJjX7CPWZLJ20kXA0CtODs59MGZDvFJPlcf8FFyWjpYK2I4WFKAOOs-DpOayZVa3AbQvD6MfDVrLGNW3mk3cUtiiw==\">ADA guidelines hypertension T2DM</a>\n",
      "  </div>\n",
      "</div>\n",
      "\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "from google import genai\n",
    "from google.genai.types import Tool, GenerateContentConfig, GoogleSearch\n",
    "from dotenv import load_dotenv\n",
    "\n",
    "load_dotenv()\n",
    "api_key = os.getenv(\"GEMINI_API_KEY\")\n",
    "if not api_key:\n",
    "    raise ValueError(\"❌ GEMINI_API_KEY not found in .env\")\n",
    "\n",
    "client = genai.Client(api_key=api_key)\n",
    "\n",
    "\n",
    "\n",
    "client = genai.Client()\n",
    "model_id = \"gemini-2.5-flash-preview-05-20\"\n",
    "\n",
    "google_search_tool = Tool(\n",
    "    google_search = GoogleSearch()\n",
    ")\n",
    "\n",
    "response = client.models.generate_content(\n",
    "    model=model_id,\n",
    "    contents=\"Latest guideline for HTN control for patients with T2DM.\",\n",
    "    config=GenerateContentConfig(\n",
    "        tools=[google_search_tool],\n",
    "        response_modalities=[\"TEXT\"],\n",
    "    )\n",
    ")\n",
    "\n",
    "for each in response.candidates[0].content.parts:\n",
    "    print(each.text)\n",
    "# Example response:\n",
    "# The next total solar eclipse visible in the contiguous United States will be on ...\n",
    "\n",
    "# To get grounding metadata as web content.\n",
    "print(response.candidates[0].grounding_metadata.search_entry_point.rendered_content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "22d49fe4",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The latest guidelines for hypertension (HTN) control in patients with Type 2 Diabetes Mellitus (T2DM) emphasize individualized care, intensive blood pressure (BP) targets, and a combination of lifestyle interventions and pharmacological treatment. Key recommendations from leading organizations include:\n",
      "\n",
      "**Blood Pressure Targets:**\n",
      "*   The **European Society of Cardiology (ESC) 2024 guidelines** recommend a target BP in clinical practice of 120–129/70–79 mmHg for most patients with T2DM and hypertension, if feasible and tolerated. For patients who cannot tolerate this target, a systolic BP level \"as low as reasonably achievable\" (ALARA principle) is recommended.\n",
      "*   The **American Diabetes Association (ADA) 2023/2024 Standards of Care** advise that the target BP for most people with diabetes should be below 130/80 mmHg, if it can be safely achieved. For those with higher cardiovascular (CV) risk (e.g., established atherosclerotic cardiovascular disease or a 10-year ASCVD risk ≥15%), a target of less than 130/80 mmHg is also recommended. However, some earlier ADA guidelines had a general target of <140/90 mmHg for most patients, with a more intensive target for those at higher CV risk.\n",
      "*   The **American College of Cardiology/American Heart Association (ACC/AHA) 2017 guidelines** recommend initiating pharmacological treatment and a target of <130/80 mmHg for these patients.\n",
      "*   A recent study presented at the American Heart Association's Scientific Sessions 2024 suggests that for most people with T2DM, lowering systolic blood pressure to less than 120 mmHg reduced the risk of major cardiovascular events.\n",
      "\n",
      "**Initiation of Pharmacological Treatment:**\n",
      "*   The **ESC 2024 guidelines** recommend that patients with T2DM and persistent office BP readings >140/90 mmHg, or a systolic BP of 130–139 mmHg after 3 months of lifestyle interventions, should begin antihypertensive drug therapy. For adults with confirmed elevated BP (≥130/80 mmHg) and high cardiovascular risk, pharmacological treatment is recommended after 3 months of lifestyle changes.\n",
      "*   The **ADA 2024 guidelines** state that individuals with confirmed office-based BP ≥130/80 mmHg qualify for the initiation and titration of pharmacologic therapy to achieve the recommended BP goal of <130/80 mmHg. For individuals with confirmed office-based BP ≥150/90 mmHg, prompt initiation and timely titration of two drugs or a single-pill combination are recommended in addition to lifestyle therapy.\n",
      "\n",
      "**Lifestyle Interventions:**\n",
      "*   Lifestyle interventions are a central pillar in the management of HTN in T2DM patients and are recommended for prevention, elevated BP, and treatment of hypertension. These include:\n",
      "    *   Weight loss for overweight or obese patients.\n",
      "    *   A Dietary Approaches to Stop Hypertension (DASH)-style dietary pattern, including reduced sodium, increased potassium, and increased fruit and vegetable consumption.\n",
      "    *   Moderation of alcohol intake.\n",
      "    *   Increased physical activity.\n",
      "\n",
      "**Medication Choices:**\n",
      "*   Initial treatment for hypertension in T2DM should include drug classes demonstrated to reduce cardiovascular events in these patients, such as ACE inhibitors (ACEi), angiotensin receptor blockers (ARBs), thiazide-like diuretics, or dihydropyridine calcium channel blockers (CCBs).\n",
      "*   An ACEi or ARB is suggested for patients with coronary artery disease or urine albumin-to-creatinine ratio 30–299 mg/g creatinine, and strongly recommended for those with a ratio ≥300 mg/g creatinine.\n",
      "*   Mineralocorticoid receptor antagonists (MRAs) also have benefits in reducing albuminuria in diabetic nephropathy.\n",
      "*   The ESC 2024 guidelines recognize the growing evidence for using SGLT2 inhibitors in hypertensive patients with coexisting conditions like chronic kidney disease, T2DM, and heart failure, integrating them into hypertension management for dual benefits of BP control and cardiovascular risk reduction.\n",
      "\n",
      "**Monitoring:**\n",
      "*   Blood pressure should be measured at every routine clinical care visit.\n",
      "*   Home and ambulatory BP monitoring (HBPM and ABPM) are recommended due to the frequent occurrence of white-coat hypertension, masked hypertension, and other patterns in diabetic patients. HBPM is considered more effective than clinic BP measurement in T2DM patients and provides better detection of hypertension compared to 24-hour ABPM in Asian countries.\n",
      "\n",
      "**Individualized Management:**\n",
      "*   All guidelines emphasize the importance of individualized management, considering factors such as total cardiovascular risk, age, treatment tolerability, comorbidities, frailty, and life expectancy.\n",
      "\n",
      "=== LINE Flex Message JSON ===\n",
      "\n",
      "{\n",
      "  \"type\": \"bubble\",\n",
      "  \"body\": {\n",
      "    \"type\": \"box\",\n",
      "    \"layout\": \"vertical\",\n",
      "    \"contents\": [\n",
      "      {\n",
      "        \"type\": \"text\",\n",
      "        \"text\": \"參考來源\",\n",
      "        \"weight\": \"bold\",\n",
      "        \"size\": \"lg\",\n",
      "        \"margin\": \"md\"\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"text\",\n",
      "        \"text\": \"ESC hypertension guidelines T2DM 2024\",\n",
      "        \"size\": \"md\",\n",
      "        \"color\": \"#3366CC\",\n",
      "        \"action\": {\n",
      "          \"type\": \"uri\",\n",
      "          \"uri\": \"https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGZppm13FAx6J9VXaSG5bHU5H952w76L85SB7LI8vcfIjUq5mlb4RU__c_GR5XK0tvGn7Z5Ugy70PeKo4ERN4AhCeZWCGLwZSYCES5epOaFiPlJ8AGvl453HQd2U8mUL52k-2I8qM2vkq53uA__i6WdLTvAvjujEGkXTReuPZtUUCGvQUGEF1NuOENrVo49XaYx5u3ykyGKd2RTIKeofnQRoWaR\"\n",
      "        },\n",
      "        \"margin\": \"md\",\n",
      "        \"wrap\": true\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"text\",\n",
      "        \"text\": \"AHA hypertension guidelines T2DM 2024\",\n",
      "        \"size\": \"md\",\n",
      "        \"color\": \"#3366CC\",\n",
      "        \"action\": {\n",
      "          \"type\": \"uri\",\n",
      "          \"uri\": \"https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXGsRzU8zth8dvPRBMRAQXsbPo3KPDCc5WlPjvDzE0U3OZKz2wJ9RIXkXoTy_Sa456iw0uB46M1QZ_NdA5NVGSbmZu-wMtAcPeLYaaHfkLbonRVRevjiY_FN1TO6hjyC9E6sWt9V9U1zO7B1tfslDvjSZmyOxzQDKRgpt0KBcov3ZFq_hC6rhQRDEwgy6eSZbqA5qk52iZpqkK_xkdhUcYkS_1W2\"\n",
      "        },\n",
      "        \"margin\": \"md\",\n",
      "        \"wrap\": true\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"text\",\n",
      "        \"text\": \"latest guidelines HTN control T2DM\",\n",
      "        \"size\": \"md\",\n",
      "        \"color\": \"#3366CC\",\n",
      "        \"action\": {\n",
      "          \"type\": \"uri\",\n",
      "          \"uri\": \"https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXE-q8yqCbtR-qBIlepax9rI-dufBVyGSLVPv0kf2WFC_4iryulq75DrqD7hUBp_9-GWGtayIQyjVLYp6roICLVcvqNP5BufyqTZBTO1B_XXKKrccDOnDGzZ-h1tgQ4nSUQ2M_TR_bGRiqBsSRGkQ-AINgIqM8zlvqekbZMJRGcyoexwhXISQ12tt2NWSV6Mn5wR_U98Cq62hQT24uIfPj8l\"\n",
      "        },\n",
      "        \"margin\": \"md\",\n",
      "        \"wrap\": true\n",
      "      },\n",
      "      {\n",
      "        \"type\": \"text\",\n",
      "        \"text\": \"ADA hypertension guidelines T2DM 2024\",\n",
      "        \"size\": \"md\",\n",
      "        \"color\": \"#3366CC\",\n",
      "        \"action\": {\n",
      "          \"type\": \"uri\",\n",
      "          \"uri\": \"https://vertexaisearch.cloud.google.com/grounding-api-redirect/AbF9wXEwe9YqJd7NEgnn0eoVZBWBOssZ_LA_99NpBTujLiafyPb5aJx-XiYGrYG0M25zKIOqkKjkOLxX4hxpV6774mAe6pF1dI-7V2rbwqheHjnYqDP2wvYw0tfMuouV8L3y21x5l66BGaZOn5mL2ASjApSVdmS2xx_RxuEP6kTSeMT_A4I-bATtEvEJb-RceZXKqlSSmGatA1AqD6pQZU-IPBm_NoSf\"\n",
      "        },\n",
      "        \"margin\": \"md\",\n",
      "        \"wrap\": true\n",
      "      }\n",
      "    ]\n",
      "  }\n",
      "}\n"
     ]
    }
   ],
   "source": [
    "import os\n",
    "from google import genai\n",
    "from google.genai.types import Tool, GenerateContentConfig, GoogleSearch\n",
    "from dotenv import load_dotenv\n",
    "from bs4 import BeautifulSoup\n",
    "import json\n",
    "\n",
    "# --- Load Gemini API Key ---\n",
    "load_dotenv()\n",
    "api_key = os.getenv(\"GEMINI_API_KEY\")\n",
    "if not api_key:\n",
    "    raise ValueError(\"❌ GEMINI_API_KEY not found in .env\")\n",
    "\n",
    "client = genai.Client(api_key=api_key)\n",
    "model_id = \"gemini-2.5-flash-preview-05-20\"\n",
    "\n",
    "google_search_tool = Tool(\n",
    "    google_search = GoogleSearch()\n",
    ")\n",
    "\n",
    "# --- Query Gemini Model with Google Search Tool ---\n",
    "response = client.models.generate_content(\n",
    "    model=model_id,\n",
    "    contents=\"Latest guideline for HTN control for patients with T2DM.\",\n",
    "    config=GenerateContentConfig(\n",
    "        tools=[google_search_tool],\n",
    "        response_modalities=[\"TEXT\"],\n",
    "    )\n",
    ")\n",
    "\n",
    "# Print Gemini answer (text)\n",
    "for each in response.candidates[0].content.parts:\n",
    "    print(each.text)\n",
    "\n",
    "# --- Extract HTML grounding metadata ---\n",
    "rendered_html = response.candidates[0].grounding_metadata.search_entry_point.rendered_content\n",
    "\n",
    "# --- Parse HTML to extract references (titles/URLs) ---\n",
    "soup = BeautifulSoup(rendered_html, \"html.parser\")\n",
    "refs = [\n",
    "    {\"title\": a.text.strip(), \"url\": a[\"href\"]}\n",
    "    for a in soup.find_all(\"a\", class_=\"chip\")\n",
    "]\n",
    "\n",
    "# --- Build LINE Flex Message JSON (for preview, or use with LINE SDK) ---\n",
    "def references_to_flex(refs, headline=\"參考來源\"):\n",
    "    flex_contents = {\n",
    "        \"type\": \"bubble\",\n",
    "        \"body\": {\n",
    "            \"type\": \"box\",\n",
    "            \"layout\": \"vertical\",\n",
    "            \"contents\": (\n",
    "                [{\"type\": \"text\", \"text\": headline, \"weight\": \"bold\", \"size\": \"lg\", \"margin\": \"md\"}] +\n",
    "                [\n",
    "                    {\n",
    "                        \"type\": \"text\",\n",
    "                        \"text\": r[\"title\"],\n",
    "                        \"size\": \"md\",\n",
    "                        \"color\": \"#3366CC\",\n",
    "                        \"action\": {\"type\": \"uri\", \"uri\": r[\"url\"]},\n",
    "                        \"margin\": \"md\",\n",
    "                        \"wrap\": True\n",
    "                    }\n",
    "                    for r in refs\n",
    "                ]\n",
    "            )\n",
    "        }\n",
    "    }\n",
    "    return flex_contents\n",
    "\n",
    "flex_msg_json = references_to_flex(refs)\n",
    "\n",
    "# --- Preview Flex Message JSON ---\n",
    "print(\"\\n=== LINE Flex Message JSON ===\\n\")\n",
    "print(json.dumps(flex_msg_json, ensure_ascii=False, indent=2))\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.8"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
